Fig. 2: Cysteamine decreases the production of SARS-CoV-2 variants in Vero E6 cells.
From: Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants
Supernatants from Vero E6 cells SARS-CoV-2 infected with wild type strain (A), Delta (B) and Omicron (C) variants, treated with different doses of cysteamine or H2O as indicated were harvested 72 h.p.i.. Virus yield was measured by back-titration based on detection of CPE and compared among the wild type strain, Delta and Omicron variants in absence of cysteamine (E). Infectious titers were calculated with the Reed–Muench method and expressed as 50% tissue-culture effective dose (TCID50) values. (D) The efficacy of the cysteamine treatment in Vero E6 cells was expressed as percentage of inhibition of the virus yields measured in panels A–C. Statistical analysis was performed using Wilcoxon matched-pairs rank test. Data are expressed as median ± S.D. (n = 9) of three independent experiments performed in triplicate.
